Gross NJ - Search Results

1

Nebulized formoterol fumarate: Dose selection and pharmacokinetics.

Gross NJ, Kerwin E, Levine B, Kim KT, Denis-Mize K, Hamzavi M, Carpenter M, Rinehart M. Gross NJ, et al. Pulm Pharmacol Ther. 2008 Oct;21(5):818-23. doi: 10.1016/j.pupt.2008.07.002. Epub 2008 Jul 8. Pulm Pharmacol Ther. 2008. PMID: 18655841 Clinical Trial.

2

Cardiac safety profile of nebulized formoterol in adults with COPD: a 12-week, multicenter, randomized, double- blind, double-dummy, placebo- and active-controlled trial.

Nelson HS, Gross NJ, Levine B, Kerwin EM, Rinehart M, Denis-Mize K; Formoterol Study Group. Nelson HS, et al. Among authors: gross nj. Clin Ther. 2007 Oct;29(10):2167-78. doi: 10.1016/j.clinthera.2007.10.007. Clin Ther. 2007. PMID: 18042473 Clinical Trial.

3

Efficacy and safety of formoterol fumarate delivered by nebulization to COPD patients.

Gross NJ, Nelson HS, Lapidus RJ, Dunn L, Lynn L, Rinehart M, Denis-Mize K; Formoterol Study Group. Gross NJ, et al. Respir Med. 2008 Feb;102(2):189-97. doi: 10.1016/j.rmed.2007.10.007. Respir Med. 2008. PMID: 18363201 Free article. Clinical Trial.

4

Nebulized formoterol: a review of clinical efficacy and safety in COPD.

Gross NJ, Donohue JF. Gross NJ, et al. Int J Chron Obstruct Pulmon Dis. 2010 Aug 9;5:223-32. doi: 10.2147/copd.s11006. Int J Chron Obstruct Pulmon Dis. 2010. PMID: 20714376 Free PMC article. Review.

5

Dose response to ipratropium as a nebulized solution in patients with chronic obstructive pulmonary disease. A three-center study.

Gross NJ, Petty TL, Friedman M, Skorodin MS, Silvers GW, Donohue JF. Gross NJ, et al. Am Rev Respir Dis. 1989 May;139(5):1188-91. doi: 10.1164/ajrccm/139.5.1188. Am Rev Respir Dis. 1989. PMID: 2523681 Clinical Trial.

6

Anticholinergic agents in asthma and COPD.

Gross NJ. Gross NJ. Eur J Pharmacol. 2006 Mar 8;533(1-3):36-9. doi: 10.1016/j.ejphar.2005.12.072. Epub 2006 Feb 20. Eur J Pharmacol. 2006. PMID: 16488410 Review.

7

Inhalation by nebulization of albuterol-ipratropium combination (Dey combination) is superior to either agent alone in the treatment of chronic obstructive pulmonary disease. Dey Combination Solution Study Group.

Gross N, Tashkin D, Miller R, Oren J, Coleman W, Linberg S. Gross N, et al. Respiration. 1998;65(5):354-62. doi: 10.1159/000029295. Respiration. 1998. PMID: 9782217 Clinical Trial.

8

Primary care of the patient with chronic obstructive pulmonary disease-part 2: pharmacologic treatment across all stages of disease.

Gross N, Levin D. Gross N, et al. Am J Med. 2008 Jul;121(7 Suppl):S13-24. doi: 10.1016/j.amjmed.2008.04.003. Am J Med. 2008. PMID: 18558103 Review.

9

Tiotropium bromide.

Gross NJ. Gross NJ. Chest. 2004 Dec;126(6):1946-53. doi: 10.1378/chest.126.6.1946. Chest. 2004. PMID: 15596697 Review.

10

Treatment of chronic obstructive pulmonary disease with roflumilast, a new phosphodiesterase 4 inhibitor.

Gross NJ, Giembycz MA, Rennard SI. Gross NJ, et al. COPD. 2010 Apr;7(2):141-53. doi: 10.3109/15412551003758304. COPD. 2010. PMID: 20397815 Free article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

179 results

Search Page

Filters